<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614301</url>
  </required_header>
  <id_info>
    <org_study_id>MEL001</org_study_id>
    <nct_id>NCT01614301</nct_id>
  </id_info>
  <brief_title>Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma</brief_title>
  <official_title>A Prospective Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial of Temsirolimus in Combination With Pioglitazone, Etoricoxib and Metronomic Low-dose Trofosfamide Versus Dacarbazine (DTIC) in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective phase I and consecutive phase II, twoarm, randomized multi-center trial of&#xD;
      temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose&#xD;
      trofosfamide versus dacarbazine (DTIC) in patients with advanced melanoma&#xD;
&#xD;
      Phase I: To determine the dose of temsirolimus to be used in phase II part of the study&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
      To determine overall survival Secondary objectives&#xD;
&#xD;
        -  To evalulate response rate&#xD;
&#xD;
        -  To evaluate time to progression (TTP)&#xD;
&#xD;
        -  To evalulate time to partial response (time to PR or better)(TPR)&#xD;
&#xD;
        -  To evaluate quality of life&#xD;
&#xD;
        -  To evaluate tolerability and safety&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progession</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Advanced Melanoma</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+. Treatment until disease progression or toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controll Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks. The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus</intervention_name>
    <description>Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.&#xD;
Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity</description>
    <arm_group_label>Controll Arm</arm_group_label>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Must be able to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          -  Must be histologically diagnosed with metastatic melanoma and LDH level &gt; 0.8 ULN&#xD;
&#xD;
          -  Measurable lesions&#xD;
&#xD;
          -  Subjects must receive study medication as first-line therapy. Preceeding adjuvant&#xD;
             therapies are allowed.&#xD;
&#xD;
          -  BRAF V600 mutation analysis&#xD;
&#xD;
          -  Sufficient bone marrow function: neutrophils ≥ 2x109/l, hemoglobin ≥10 g/dl, platelets&#xD;
             ≥ 100x109/l&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (see&#xD;
             Post Text Supplement 3).&#xD;
&#xD;
          -  Required laboratory results:&#xD;
&#xD;
               1. Liver function: Total bilirubin &lt; 1.5 times of upper limit of local institution&#xD;
                  (ULN), SGPT, SGOT ≤ 2.5 times of upper limit of local institution&#xD;
&#xD;
               2. Renal function: serum creatinine ≤ 1.5 ULN&#xD;
&#xD;
               3. PT-INR/PT &lt;1.5 ULN&#xD;
&#xD;
          -  Normal cardiac function&#xD;
&#xD;
          -  Patients with prior thrombembolic event with adequate anticoagulation&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
          -  Written informed consent of the patient prior to screening procedures&#xD;
&#xD;
          -  Patient must be available for treatment and follow-up&#xD;
&#xD;
          -  Adequate contraception in women capable of bearing children and men with partner&#xD;
             capable of bearing children (combined oral contraceptives, hormonereleasing&#xD;
             intrauterine contraceptive device, hormonal contraceptive implants, hormonal&#xD;
             contraceptive injectables, surgical sterilization)&#xD;
&#xD;
          -  Any previous surgery must have taken place more than 4 weeks prior to inclusion&#xD;
&#xD;
          -  Previous radiation therapy must have involved less than 25% of bone marrow, and must&#xD;
             have been completed more than 4 weeks prior to inclusion.&#xD;
&#xD;
          -  For patients with controlled diabetes mellitus glucose levels have to be monitored&#xD;
             continuously and the treating diabetologist has to be informed about the study&#xD;
             participation of the patient.&#xD;
&#xD;
          -  Patients with wild-type BRAF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented brain metastases unless the patient has completed successful local therapy&#xD;
             for central nervous system metastases and has been off of corticosteroids for at least&#xD;
             4 weeks before enrollment.&#xD;
&#xD;
          -  Patients who require vitamin K antagonists except for low dose&#xD;
&#xD;
          -  Patients with bladder cancer or bladder cancer in their medical history, patients with&#xD;
             risk factors for bladder cancer (such as exposure to aromatic amines or heavy tobacco&#xD;
             smokers), or macrohematuria of unknown origin&#xD;
&#xD;
          -  Prior history of stroke&#xD;
&#xD;
          -  Known hypersensitivity to study drugs or to any of the excipients&#xD;
&#xD;
          -  Active infection &gt; grade 2 NCI-CTC version 4.0&#xD;
&#xD;
          -  Known diagnosis of HIV, hepatitis B, or hepatitis C infection.&#xD;
&#xD;
          -  Severe, unstable, or uncontrolled medical disease which would confound diagnoses or&#xD;
             evaluations required by the protocol, including cardiac insufficiency (NYHA I -IV)&#xD;
             uncontrolled diabetes including diabetic ketoacidosis, chronic hepatic or renal&#xD;
             disease, active uncontrolled infection and chronic inflammatory intestinal disease,&#xD;
             autoimmune diseases, peripheral arterial disease, verified coronary heart disease,&#xD;
             cerebrovascular disease, acute peptic ulcer or acute gastro-intestinal bleeding.&#xD;
&#xD;
          -  Prior radiation therapy &gt; 25% of bone marrow&#xD;
&#xD;
          -  Regular blood transfusions&#xD;
&#xD;
          -  Treatment with other experimental substances within 30 days before study start&#xD;
&#xD;
          -  Prior immunotherapy with ipilimumab, vaccination, B-raf inhibitor&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days before study start or during&#xD;
             the trial&#xD;
&#xD;
          -  Unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Pregnant or breastfeeding patients. Women of childbearing potential must have a&#xD;
             negative pregnancy test performed 7 days prior start of treatment.&#xD;
&#xD;
          -  Patients with seizure disorders requiring medication (such as steroids or&#xD;
             antiepileptics)&#xD;
&#xD;
          -  Patients with evidence or history of bleeding diathesis&#xD;
&#xD;
          -  Patients undergoing renal dialysis&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to start of study or incomplete wound healing&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Psychological or social conditions that may interfere with the patients participation&#xD;
             in the study or evaluation of the study results.&#xD;
&#xD;
          -  Known (at time of entry) gastrointestinal disorder, including malabsorbtion or active&#xD;
             gastric ulcer, present to the extent that it might interfere with oral intake and&#xD;
             absorption of study medication&#xD;
&#xD;
          -  Patients undergoing dialysis or creatinine clearance &lt;30 mL per minute, defined&#xD;
             according to MDRD&#xD;
&#xD;
          -  Patients with medically uncontrolled hypertension (RR continuously &gt; 140/90 mm Hg)&#xD;
&#xD;
          -  Any previous or concurrent malignancy or any cancer unless curatively treated &gt; 3&#xD;
             years prior to study entry except cervical carcinoma in situ or adequate basal cell&#xD;
             carcinoma&#xD;
&#xD;
          -  Any urothelial cell carcinoma in the medical history&#xD;
&#xD;
          -  Patients who have experienced bronchospasm, acute rhinitis, nasal polyps,&#xD;
             angioneurotic oedema, urticaria, or allergic type reactions after acetylsalicylic acid&#xD;
             or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors&#xD;
&#xD;
          -  Patients with BRAF V600 mutant metastatic melanoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albrecht Reichle, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrecht Reichle, Professor</last_name>
      <phone>+499419440</phone>
      <email>albrecht.reichle@UKR.de</email>
    </contact>
    <investigator>
      <last_name>Martin Vogelhuber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Mayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Hart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Grube, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanne Gantner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Albrecht Reichle</investigator_full_name>
    <investigator_title>Professor MD</investigator_title>
  </responsible_party>
  <keyword>advanced Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Trofosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

